G-CSF After Chemo-radiation in Patients With Glioblastoma

This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation. The study aims to evaluate G-CSF's effects on brain health and cognitive function. The name of the study drugs involved in this study are: * G-CSF (also called Filgrastim) * Temozolomide (TMZ), a standard of care chemotherapy drug

Trial Details

NCT ID
NCT06649851
Phase
PHASE2
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Granulocyte Colony Stimulating Factor (G-CSF)
  • Radiation Therapy + Temozolomide
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have confirmed newly diagnosed glioblastoma multiforme (GBM), World Health Organization (WHO) grade 4, IDH wildtype, either by hi…
  • Molecular analysis needs to confirm a positive MGMT promoter methylation status using standard institutional testing methods.
  • Treatment needs to involve a planned 6-week course of standard of care radiation therapy with concurrent and adjuvant 6 monthly chemotherapy with t…
  • Age ≥18 years. GBM is considered a biologically distinct disease in children. Children are excluded from this study but will be eligible for future…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →